Micafungin: Difference between revisions

No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 3: Line 3:
*Dosage Forms:  
*Dosage Forms:  
*Routes of Administration: Intravenous
*Routes of Administration: Intravenous
*Common Trade Names:  
*Common Trade Names: Mycamine


==Adult Dosing==
==Adult Dosing==
*Candidiasis or aspergillosis treatment: 50-150mg IV daily
*[[Candidiasis]] or [[aspergillosis]] treatment: 50-150mg IV daily
*Antifungal prophylaxis: 1mg/kg IV daily  
*Antifungal prophylaxis: 1mg/kg IV daily


==Pediatric Dosing==
==Pediatric Dosing==
Line 50: Line 50:
*[[Antifungal]]
*[[Antifungal]]
*[[Candidiasis]], [[Aspergillosis]]
*[[Candidiasis]], [[Aspergillosis]]
*[[Fungal infections]]


==References==
==References==
<references/>
<references/>
[[Category:Pharmacology]] [[Category:ID]]
[[Category:Pharmacology]] [[Category:ID]]

Latest revision as of 10:02, 3 January 2022

Administration

  • Type: Antifungal
  • Dosage Forms:
  • Routes of Administration: Intravenous
  • Common Trade Names: Mycamine

Adult Dosing

Pediatric Dosing

  • <4mo, <40kg: 2-3mg/kg IV daily
  • <4mo, >40kg: 100-150 mg IV daily

Special Populations

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Atrial fibrillation, MI, pericardial effusion, cardiac arrest
  • Anemia, hemolysis
  • Liver failure, hepatitis
  • Encephalopathy
  • Intracranial hemorrhage
  • Seizure
  • Acute renal failure

Common

  • Nausea, vomiting, diarrhea
  • Headache
  • Fever
  • Thrombocytopenia

Pharmacology

  • Half-life: 5.5-21h
  • Metabolism: Hepatic, mostly CYP3A
  • Excretion: Mostly fecal

Mechanism of Action

  • Inhibits the synthesis of vital fungal cell wall component 1,3 beta-D-glucan

Comments

See Also

References